Blog
Blog
The CI Capacity Squeeze, and Three Questions To Ask Before 2027 Planning
Every year the competitive field gets more crowded: more assets, more readouts, more congress abstracts, more competitor moves to track. Products are more complex too, from special distribution to patient and healthcare professional (HCP) education requirements. And every year, pharma competitive intelligence (CI) teams are asked to cover more of it. What’s changed is that resources aren’t keeping up.
Filter posts by:
Blog
Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future
Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which...
Blog
Japan Pricing Policy Reform 2024
Executive Summary The Central Social Insurance Medical Council, the key Japanese reimbursement policy panel known as Chuikyo, introduced the 2024 drug pricing reform in April 2024. Some key features of the reform plan include: The reform outlines a suite of measures aimed at...
Blog
Rise with the Waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future
Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to...
Blog
Rise with the Waves: Canada – A Coming (R)evolution: Transforming Pharmaceutical Market Access
Executive Summary Canada has undertaken meaningful strategies to transform patient access and ultimately improve health outcomes across the country. Two such potentially high-impact strategies include the planned transformation of the former Canadian Agency for Drugs and Technology in Health (CADTH) into...
Blog
Using Transparency in Coverage Reimbursement Insights to Inform Payer and Provider Contracting Strategy
Executive Summary “Transparency in Coverage” (TIC) data is a newer data source that has recently become available for mining unique insights in the reimbursement/economics between payers and providers. In 2020, the Federal Government TIC Rule required health insurers and group health...
Blog
Rise with the Waves: Italy – AIFA Restructuring and Budget Reforms – Stepping into a New (Uncertain) Future?
Executive Summary The Italian Medicines Agency (AIFA) underwent transformative changes on January 30, 2024, following a much-anticipated reorganization. AIFA’s restructuring has already faced challenges, with the recent resignation of the newly created Scientific and Economic Commission’s (CSE) chairman followed by the...
